Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1996 Mar;122(3):181–185. doi: 10.1007/BF01366960

The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary

A van der Gaast 1,2,✉, J Verweij 1,2, A S Th Planting 1,2, G Stoter 1,2, S C Henzen-Logmans 3
PMCID: PMC12201528  PMID: 8601568

Abstract

A subgroup of patients with metastatic carcinomas of unknown origin may benefit from combination chemotherapy. The relevance of immunohistochemistry in detecting such patients was investigated. Immunohistochemical studies with a panel of antibodies were performed on the tissue specimens of 41 patients having a light-microscopic diagnosis of poorly differentiated adenocarcinoma or undifferentiated carcinoma of unknown origin, who had been treated with cisplatin-containing chemotherapy. The study aimed to answer the following questions: (a) Can the tissue type of the tumor be verified? (b) Can a primary organ site be identified? (c) Can a prognostic immunohistochemical profile be recognized? The original diagnosis had to be changed in 2 of the 41 patients, who turned out to have a malignant lymphoma and neuroblastoma, respectively. The primary site was diagnosed in a patient with prostate cancer, whereas in one case the diagnosis could be narrowed down to a neuroendocrine tumor. No certain immunohistochemical profile with prognostic significance could be identified. It was concluded that immunohistochemistry should be routinely used in cases of undifferentiated carcinoma of unknown primary origin to verify the histological diagnosis and to select the appropriate therapy.

Key words: Carcinoma of unknown origin, Immunohistochemistry, Chemotherapy

Abbreviations

ßHCG

β-human chorionic gonadotropin

AFP

α-fetoprotein

CEA

careinoembryonic antigen

PSA

prostate-specific antigen

PZF

prostatic acid phosphatase

References

  1. Didolkar MS, Fanous N, Elias EG, Moore RH (1977) Metastatic carcinomas from occult primary tumor: a study of 254 patients. Ann Surg 186:625–630 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Domagala W, Lasota J, Bartowiak J, Weber K, Osborn M (1990) Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 136:219–227 [PMC free article] [PubMed] [Google Scholar]
  3. Gaast A van der, Verweij J, Henzen-Logmans SC, Stoter G (1990) Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol 1:119–122 [DOI] [PubMed] [Google Scholar]
  4. Goslin R, O'Brien MJ, Steele G, Mayer R, Wilson R, Corson JM, Zamcheck N (1981) Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal carcinoma. Am J Med 71:246–253 [DOI] [PubMed] [Google Scholar]
  5. Greco FA, Hainsworth JD (1990) Carcinoma of unknown primary site. Ann Oncol 1:98–99 [DOI] [PubMed] [Google Scholar]
  6. Greco FA, Vaughn WK, Hainsworth JD (1986) Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 104:547–553 [DOI] [PubMed] [Google Scholar]
  7. Hainsworth JD, Dial TW, Greco FA (1988) Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site. Am J Clin Oncol 11: 138–145 [DOI] [PubMed] [Google Scholar]
  8. Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA (1991) Poorly differentiated carcinoma of unknown primary site: Clinical usefulness of immunoperoxidase staining. J Clin Oncol 9:1931–1938 [DOI] [PubMed] [Google Scholar]
  9. Hainsworth JD, Johnson DH, Greco FA (1992a) Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 10:912–922 [DOI] [PubMed] [Google Scholar]
  10. Hainsworth JD, Johnson DH, Greco FA (1992b) The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site. Semin Oncol 19 [Suppl 5]:54–58 [PubMed] [Google Scholar]
  11. Henzen-Logmans SC, Mullink H, Vennegoor C, Hilgers J, Oort J, Meijer JLM (1987) Classification of routinely processed anaplastic large cell tumours with a small panel of antibodies. An immunohistochemical study with clinical follow-up. Histol Histopathol 2:107–118 [PubMed] [Google Scholar]
  12. Holmes FF, Fouts TL (1990) Metastatic cancer of unknown primary site. Cancer 26:816–820 [DOI] [PubMed] [Google Scholar]
  13. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457–481 [Google Scholar]
  14. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielman N, Rouesse J (1988) Early metastatic cancer of unknown primary origin at presentation: a clinical study of 302 consecutive autopsied patients. Arch Intern Med 148: 2035–2039 [PubMed] [Google Scholar]
  15. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170 [PubMed] [Google Scholar]
  16. Neumann KH, Nystrom JS (1982) Metastatic cancer of unknown origin; nonsquamous cell type. Semin Oncol 4:427–434 [PubMed] [Google Scholar]
  17. Nystrom JS, Weiner JM, Wolf RM, Bateman JR, Viola MV (1979) Identifying the primary site in metastatic cancer of unknown origin: inadequacy of roentgenographic procedures. JAMA 241:381–383 [PubMed] [Google Scholar]
  18. Raymond WA, Leong A S-Y (1989) Vimentin — a new prognostic parameter in breast carcinoma? J Pathol 158:107–114 [DOI] [PubMed] [Google Scholar]
  19. Ultmann JE (1991) Cancer of unknown primary site. J Cancer Res Clin Oncol 117:505–509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Vennegoor C, Calafat J, Hageman Ph, van Buitenen F, Janssen H, Kolk A, Rumke Ph (1985) Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI/C-3. Int J Cancer 35:287–295 [DOI] [PubMed] [Google Scholar]
  21. WHO (1979) Handbook of reporting results of cancer treatment: WHO offset Publ 48
  22. Woods RL, Fox RM, Tattersall MHN, Levi JA, Brodie GN (1980) Metastatic adenocarcinomas of unknown primary: a randomized study of two combination-chemotherapy regimens. N. Engl J Med 303:87–89 [DOI] [PubMed] [Google Scholar]
  23. Zarbo RJ, Gown AM, Nagle RB, Visscher DW, Crissman JD (1990) Anomalous cytokeratin expression in malignant melanoma: one- and two-dimensional Western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol 3:494–501 [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES